Prevalence of targeted therapy-related genetic variations in NSCLC and their relationship with clinicopathological characteristics
Non-small cell lung cancer (NSCLC) is the most common cancer type in China. Targeted therapies have been used to treat NSCLC for two decades, which is only suitable for a subgroup of patients with specific genetic variations. The aim of this study was to investigate the prevalence of genetic variati...
Saved in:
Published in | PloS one Vol. 17; no. 1; p. e0262822 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
21.01.2022
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Non-small cell lung cancer (NSCLC) is the most common cancer type in China. Targeted therapies have been used to treat NSCLC for two decades, which is only suitable for a subgroup of patients with specific genetic variations. The aim of this study was to investigate the prevalence of genetic variations leading to sensitivity or resistance to targeted therapies in NSCLC, and their relationship with clinicopathological characteristics of the patients.
Tumor samples were collected from 404 patients who were diagnosed to have NSCLC and underwent surgery, transthoracic biopsy, bronchoscopy biopsy, or pleural aspiration in Sichuan Provincial People's Hospital from January 2019 to March 2020. Commercial amplification-refractory mutation system kits were used to detect targeted therapy-related genetic variations in those tumor samples. The prevalence of genetic variations and their relationship with patient clinicopathological characteristics were analyzed using statistical software, followed by subgroup analysis.
In all, 50.7% of the NSCLC patients had sensitive genetic variations to anti-EGFR therapies, and 4.9% of those patients had co-existing resistant genetic variations. Fusions in ALK, ROS1, or RET were found in 7.7% of the patients, including 2 patients with co-existing EGFR exon 19 deletion or L858R. EGFR exon 19 deletion and L858R were more common in female patients and adenocarcinoma. Further subgroup analysis confirmed the observation in female patients in adenocarcinoma subgroup, and in adenocarcinoma in male patients. In addition, smokers were more likely to have squamous cell carcinoma and KRAS mutation and less likely to have EGFR L858R, which were also confirmed after standardization of gender except KRAS mutations.
Nearly half of the NSCLC patients were eligible for anti-EGFR treatments. In NSCLC, female gender and adenocarcinoma may indicate higher chance of EGFR exon 19 deletion or L858R, and smoking history may indicate squamous cell carcinoma and EGFR L858R. |
---|---|
AbstractList | Background
Non-small cell lung cancer (NSCLC) is the most common cancer type in China. Targeted therapies have been used to treat NSCLC for two decades, which is only suitable for a subgroup of patients with specific genetic variations. The aim of this study was to investigate the prevalence of genetic variations leading to sensitivity or resistance to targeted therapies in NSCLC, and their relationship with clinicopathological characteristics of the patients.
Methods
Tumor samples were collected from 404 patients who were diagnosed to have NSCLC and underwent surgery, transthoracic biopsy, bronchoscopy biopsy, or pleural aspiration in Sichuan Provincial People’s Hospital from January 2019 to March 2020. Commercial amplification-refractory mutation system kits were used to detect targeted therapy-related genetic variations in those tumor samples. The prevalence of genetic variations and their relationship with patient clinicopathological characteristics were analyzed using statistical software, followed by subgroup analysis.
Results
In all, 50.7% of the NSCLC patients had sensitive genetic variations to anti-EGFR therapies, and 4.9% of those patients had co-existing resistant genetic variations. Fusions in ALK, ROS1, or RET were found in 7.7% of the patients, including 2 patients with co-existing EGFR exon 19 deletion or L858R. EGFR exon 19 deletion and L858R were more common in female patients and adenocarcinoma. Further subgroup analysis confirmed the observation in female patients in adenocarcinoma subgroup, and in adenocarcinoma in male patients. In addition, smokers were more likely to have squamous cell carcinoma and KRAS mutation and less likely to have EGFR L858R, which were also confirmed after standardization of gender except KRAS mutations.
Conclusion
Nearly half of the NSCLC patients were eligible for anti-EGFR treatments. In NSCLC, female gender and adenocarcinoma may indicate higher chance of EGFR exon 19 deletion or L858R, and smoking history may indicate squamous cell carcinoma and EGFR L858R. Background Non-small cell lung cancer (NSCLC) is the most common cancer type in China. Targeted therapies have been used to treat NSCLC for two decades, which is only suitable for a subgroup of patients with specific genetic variations. The aim of this study was to investigate the prevalence of genetic variations leading to sensitivity or resistance to targeted therapies in NSCLC, and their relationship with clinicopathological characteristics of the patients. Methods Tumor samples were collected from 404 patients who were diagnosed to have NSCLC and underwent surgery, transthoracic biopsy, bronchoscopy biopsy, or pleural aspiration in Sichuan Provincial People’s Hospital from January 2019 to March 2020. Commercial amplification-refractory mutation system kits were used to detect targeted therapy-related genetic variations in those tumor samples. The prevalence of genetic variations and their relationship with patient clinicopathological characteristics were analyzed using statistical software, followed by subgroup analysis. Results In all, 50.7% of the NSCLC patients had sensitive genetic variations to anti-EGFR therapies, and 4.9% of those patients had co-existing resistant genetic variations. Fusions in ALK , ROS1 , or RET were found in 7.7% of the patients, including 2 patients with co-existing EGFR exon 19 deletion or L858R. EGFR exon 19 deletion and L858R were more common in female patients and adenocarcinoma. Further subgroup analysis confirmed the observation in female patients in adenocarcinoma subgroup, and in adenocarcinoma in male patients. In addition, smokers were more likely to have squamous cell carcinoma and KRAS mutation and less likely to have EGFR L858R, which were also confirmed after standardization of gender except KRAS mutations. Conclusion Nearly half of the NSCLC patients were eligible for anti-EGFR treatments. In NSCLC, female gender and adenocarcinoma may indicate higher chance of EGFR exon 19 deletion or L858R, and smoking history may indicate squamous cell carcinoma and EGFR L858R. Background Non-small cell lung cancer (NSCLC) is the most common cancer type in China. Targeted therapies have been used to treat NSCLC for two decades, which is only suitable for a subgroup of patients with specific genetic variations. The aim of this study was to investigate the prevalence of genetic variations leading to sensitivity or resistance to targeted therapies in NSCLC, and their relationship with clinicopathological characteristics of the patients. Methods Tumor samples were collected from 404 patients who were diagnosed to have NSCLC and underwent surgery, transthoracic biopsy, bronchoscopy biopsy, or pleural aspiration in Sichuan Provincial People’s Hospital from January 2019 to March 2020. Commercial amplification-refractory mutation system kits were used to detect targeted therapy-related genetic variations in those tumor samples. The prevalence of genetic variations and their relationship with patient clinicopathological characteristics were analyzed using statistical software, followed by subgroup analysis. Results In all, 50.7% of the NSCLC patients had sensitive genetic variations to anti-EGFR therapies, and 4.9% of those patients had co-existing resistant genetic variations. Fusions in ALK, ROS1, or RET were found in 7.7% of the patients, including 2 patients with co-existing EGFR exon 19 deletion or L858R. EGFR exon 19 deletion and L858R were more common in female patients and adenocarcinoma. Further subgroup analysis confirmed the observation in female patients in adenocarcinoma subgroup, and in adenocarcinoma in male patients. In addition, smokers were more likely to have squamous cell carcinoma and KRAS mutation and less likely to have EGFR L858R, which were also confirmed after standardization of gender except KRAS mutations. Conclusion Nearly half of the NSCLC patients were eligible for anti-EGFR treatments. In NSCLC, female gender and adenocarcinoma may indicate higher chance of EGFR exon 19 deletion or L858R, and smoking history may indicate squamous cell carcinoma and EGFR L858R. Non-small cell lung cancer (NSCLC) is the most common cancer type in China. Targeted therapies have been used to treat NSCLC for two decades, which is only suitable for a subgroup of patients with specific genetic variations. The aim of this study was to investigate the prevalence of genetic variations leading to sensitivity or resistance to targeted therapies in NSCLC, and their relationship with clinicopathological characteristics of the patients. Tumor samples were collected from 404 patients who were diagnosed to have NSCLC and underwent surgery, transthoracic biopsy, bronchoscopy biopsy, or pleural aspiration in Sichuan Provincial People's Hospital from January 2019 to March 2020. Commercial amplification-refractory mutation system kits were used to detect targeted therapy-related genetic variations in those tumor samples. The prevalence of genetic variations and their relationship with patient clinicopathological characteristics were analyzed using statistical software, followed by subgroup analysis. In all, 50.7% of the NSCLC patients had sensitive genetic variations to anti-EGFR therapies, and 4.9% of those patients had co-existing resistant genetic variations. Fusions in ALK, ROS1, or RET were found in 7.7% of the patients, including 2 patients with co-existing EGFR exon 19 deletion or L858R. EGFR exon 19 deletion and L858R were more common in female patients and adenocarcinoma. Further subgroup analysis confirmed the observation in female patients in adenocarcinoma subgroup, and in adenocarcinoma in male patients. In addition, smokers were more likely to have squamous cell carcinoma and KRAS mutation and less likely to have EGFR L858R, which were also confirmed after standardization of gender except KRAS mutations. Nearly half of the NSCLC patients were eligible for anti-EGFR treatments. In NSCLC, female gender and adenocarcinoma may indicate higher chance of EGFR exon 19 deletion or L858R, and smoking history may indicate squamous cell carcinoma and EGFR L858R. BACKGROUNDNon-small cell lung cancer (NSCLC) is the most common cancer type in China. Targeted therapies have been used to treat NSCLC for two decades, which is only suitable for a subgroup of patients with specific genetic variations. The aim of this study was to investigate the prevalence of genetic variations leading to sensitivity or resistance to targeted therapies in NSCLC, and their relationship with clinicopathological characteristics of the patients. METHODSTumor samples were collected from 404 patients who were diagnosed to have NSCLC and underwent surgery, transthoracic biopsy, bronchoscopy biopsy, or pleural aspiration in Sichuan Provincial People's Hospital from January 2019 to March 2020. Commercial amplification-refractory mutation system kits were used to detect targeted therapy-related genetic variations in those tumor samples. The prevalence of genetic variations and their relationship with patient clinicopathological characteristics were analyzed using statistical software, followed by subgroup analysis. RESULTSIn all, 50.7% of the NSCLC patients had sensitive genetic variations to anti-EGFR therapies, and 4.9% of those patients had co-existing resistant genetic variations. Fusions in ALK, ROS1, or RET were found in 7.7% of the patients, including 2 patients with co-existing EGFR exon 19 deletion or L858R. EGFR exon 19 deletion and L858R were more common in female patients and adenocarcinoma. Further subgroup analysis confirmed the observation in female patients in adenocarcinoma subgroup, and in adenocarcinoma in male patients. In addition, smokers were more likely to have squamous cell carcinoma and KRAS mutation and less likely to have EGFR L858R, which were also confirmed after standardization of gender except KRAS mutations. CONCLUSIONNearly half of the NSCLC patients were eligible for anti-EGFR treatments. In NSCLC, female gender and adenocarcinoma may indicate higher chance of EGFR exon 19 deletion or L858R, and smoking history may indicate squamous cell carcinoma and EGFR L858R. Non-small cell lung cancer (NSCLC) is the most common cancer type in China. Targeted therapies have been used to treat NSCLC for two decades, which is only suitable for a subgroup of patients with specific genetic variations. The aim of this study was to investigate the prevalence of genetic variations leading to sensitivity or resistance to targeted therapies in NSCLC, and their relationship with clinicopathological characteristics of the patients. Tumor samples were collected from 404 patients who were diagnosed to have NSCLC and underwent surgery, transthoracic biopsy, bronchoscopy biopsy, or pleural aspiration in Sichuan Provincial People's Hospital from January 2019 to March 2020. Commercial amplification-refractory mutation system kits were used to detect targeted therapy-related genetic variations in those tumor samples. The prevalence of genetic variations and their relationship with patient clinicopathological characteristics were analyzed using statistical software, followed by subgroup analysis. In all, 50.7% of the NSCLC patients had sensitive genetic variations to anti-EGFR therapies, and 4.9% of those patients had co-existing resistant genetic variations. Fusions in ALK, ROS1, or RET were found in 7.7% of the patients, including 2 patients with co-existing EGFR exon 19 deletion or L858R. EGFR exon 19 deletion and L858R were more common in female patients and adenocarcinoma. Further subgroup analysis confirmed the observation in female patients in adenocarcinoma subgroup, and in adenocarcinoma in male patients. In addition, smokers were more likely to have squamous cell carcinoma and KRAS mutation and less likely to have EGFR L858R, which were also confirmed after standardization of gender except KRAS mutations. Nearly half of the NSCLC patients were eligible for anti-EGFR treatments. In NSCLC, female gender and adenocarcinoma may indicate higher chance of EGFR exon 19 deletion or L858R, and smoking history may indicate squamous cell carcinoma and EGFR L858R. |
Audience | Academic |
Author | Zhang, Yihao Ye, Peng Sun, Xingwang Dong, Dandan Li, Fanghua Yang, Yue Cai, Peiling |
AuthorAffiliation | 3 Department of Anatomy and Histology, College of Medicine, Chengdu University, Chengdu, China 2 Department of Pathology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, China Osmania University, Hyderabad, India, INDIA 1 Department of Pathology, Affiliated Hospital of Southwest Medical University, Luzhou, China |
AuthorAffiliation_xml | – name: 2 Department of Pathology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, China – name: 3 Department of Anatomy and Histology, College of Medicine, Chengdu University, Chengdu, China – name: 1 Department of Pathology, Affiliated Hospital of Southwest Medical University, Luzhou, China – name: Osmania University, Hyderabad, India, INDIA |
Author_xml | – sequence: 1 givenname: Fanghua surname: Li fullname: Li, Fanghua organization: Department of Pathology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China – sequence: 2 givenname: Peng surname: Ye fullname: Ye, Peng organization: Department of Anatomy and Histology, College of Medicine, Chengdu University, Chengdu, China – sequence: 3 givenname: Peiling surname: Cai fullname: Cai, Peiling organization: Department of Anatomy and Histology, College of Medicine, Chengdu University, Chengdu, China – sequence: 4 givenname: Dandan surname: Dong fullname: Dong, Dandan organization: Department of Pathology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China – sequence: 5 givenname: Yihao surname: Zhang fullname: Zhang, Yihao organization: Department of Anatomy and Histology, College of Medicine, Chengdu University, Chengdu, China – sequence: 6 givenname: Yue surname: Yang fullname: Yang, Yue organization: Department of Pathology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China – sequence: 7 givenname: Xingwang orcidid: 0000-0001-9968-1851 surname: Sun fullname: Sun, Xingwang organization: Department of Pathology, Affiliated Hospital of Southwest Medical University, Luzhou, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35061839$$D View this record in MEDLINE/PubMed |
BookMark | eNqNk01v1DAQhiNURNuFf4AgEhKCwy6xnQ_nglSt-FhpRREFrtbEmSSuvPbW9i70yi_H-9FqF_WAckgyfuadyTuZ8-TEWINJ8pxkE8Iq8u7arpwBPVnG8CSjJeWUPkrOSM3ouKQZOzl4Pk3Ovb_OsoLxsnySnLIiKwln9Vny56vDNWg0ElPbpQFcjwHbNAzoYHk7dqhh896jwaBkuganIChrfKpM-uVqOp-mYLa8cumW3hwOapn-UmFIpVZGSbuEMFhteyVBp3IABzKgUz5K-qfJ4w60x2f7-yj58fHD9-nn8fzy02x6MR_LMidhTHlRy7pgiHkpW8KKHCmUnSxom7XQkAbzoi7briF5VZG8AZI1FQdsKLCmKjo2Sl7udJfaerG3z4voHKlJGQUjMdsRrYVrsXRqAe5WWFBiG7CuF-BiyxqFbKumoF3JO2A572IdWkV3GeeE1thC1Hq_r7ZqFthKNMGBPhI9PjFqEL1dC17FQdY8CrzZCzh7s0IfxEJ5iVqDQbva9k0p5zR2Pkpe_YM-_HV7qo_zFsp0NtaVG1FxUdZZVhd1RiM1eYCKV4uLOEiDnYrxo4S3RwmRCfg79LDyXsyuvv0_e_nzmH19wA4IOgze6tX2_zoG8x0onfXeYXdvMsnEZlXu3BCbVRH7VYlpLw4HdJ90txvsL6RREvA |
Cites_doi | 10.1097/MD.0000000000001949 10.18632/oncotarget.12587 10.1016/j.jtho.2016.11.2231 10.1016/j.lungcan.2016.10.010 10.3389/fonc.2020.01251 10.1158/2159-8290.CD-12-0387 10.1056/NEJMoa0810699 10.1126/scitranslmed.3002003 10.1016/j.heliyon.2018.e01031 10.1158/1535-7163.MCT-12-0620 10.1002/ijc.32716 10.1038/s41392-019-0038-9 10.21037/atm.2016.12.33 10.1038/nature25183 10.1002/ijc.27339 10.1056/NEJMoa1406766 10.1200/JCO.2016.70.9352 10.1056/NEJMoa1214886 10.1056/NEJMoa2103695 10.1016/S1470-2045(16)00077-2 10.1038/nrc2088 10.1016/j.lungcan.2018.07.013 10.1016/j.lungcan.2006.06.003 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2022 Public Library of Science 2022 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 Li et al 2022 Li et al |
Copyright_xml | – notice: COPYRIGHT 2022 Public Library of Science – notice: 2022 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 Li et al 2022 Li et al |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PIMPY PQEST PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
DOI | 10.1371/journal.pone.0262822 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest Central Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection ProQuest Biological Science Collection Agriculture Science Database Health & Medical Collection (Alumni Edition) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Publicly Available Content database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Biological Science Collection ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic Technology Collection Technology Research Database Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE Agricultural Science Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Sciences (General) |
DocumentTitleAlternate | Genetic variations and clinicopathological characteristics in NSCLC |
EISSN | 1932-6203 |
Editor | Kancha, Rama Krishna |
Editor_xml | – sequence: 1 givenname: Rama Krishna surname: Kancha fullname: Kancha, Rama Krishna |
EndPage | e0262822 |
ExternalDocumentID | 2621916135 oai_doaj_org_article_cd7b52f68fa348f8ae27538388129eda A690095902 10_1371_journal_pone_0262822 35061839 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | China United States--US |
GeographicLocations_xml | – name: China – name: United States--US |
GrantInformation_xml | – fundername: ; grantid: No. 18CZ0044/No. 14JC0084 |
GroupedDBID | --- 123 29O 2WC 3V. 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ADBBV ADRAZ AEAQA AENEX AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BBORY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CGR CS3 CUY CVF D1I D1J D1K DIK DU5 E3Z EAP EAS EBD ECM EIF EMOBN ESTFP ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IHR IHW INH INR IOV IPNFZ IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ NPM O5R O5S OK1 P2P P62 PATMY PDBOC PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RIG RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM AAYXX CITATION 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PQEST PQUKI PRINS RC3 7X8 5PM AAPBV ABPTK N95 |
ID | FETCH-LOGICAL-c641t-2859c953ee46cd1354e2a6fc52d0dab1be4596dfb147714ba10b78aeb2a3b75f3 |
IEDL.DBID | RPM |
ISSN | 1932-6203 |
IngestDate | Sun Aug 06 00:15:57 EDT 2023 Fri Jul 05 11:53:57 EDT 2024 Tue Sep 17 21:27:52 EDT 2024 Wed Jul 24 19:19:27 EDT 2024 Mon Oct 07 11:38:09 EDT 2024 Thu Feb 22 23:57:35 EST 2024 Fri Feb 02 04:27:43 EST 2024 Thu Aug 01 20:32:48 EDT 2024 Thu Aug 01 19:57:55 EDT 2024 Tue Aug 20 22:14:56 EDT 2024 Fri Aug 23 01:58:21 EDT 2024 Sat Sep 28 08:22:33 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c641t-2859c953ee46cd1354e2a6fc52d0dab1be4596dfb147714ba10b78aeb2a3b75f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Competing Interests: Enter: The authors have declared that no competing interests exist. |
ORCID | 0000-0001-9968-1851 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8782298/ |
PMID | 35061839 |
PQID | 2621916135 |
PQPubID | 1436336 |
PageCount | e0262822 |
ParticipantIDs | plos_journals_2621916135 doaj_primary_oai_doaj_org_article_cd7b52f68fa348f8ae27538388129eda pubmedcentral_primary_oai_pubmedcentral_nih_gov_8782298 proquest_miscellaneous_2622288261 proquest_journals_2621916135 gale_infotracmisc_A690095902 gale_infotracacademiconefile_A690095902 gale_incontextgauss_ISR_A690095902 gale_incontextgauss_IOV_A690095902 gale_healthsolutions_A690095902 crossref_primary_10_1371_journal_pone_0262822 pubmed_primary_35061839 |
PublicationCentury | 2000 |
PublicationDate | 2022-01-21 |
PublicationDateYYYYMMDD | 2022-01-21 |
PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-21 day: 21 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
PublicationTitle | PloS one |
PublicationTitleAlternate | PLoS One |
PublicationYear | 2022 |
Publisher | Public Library of Science Public Library of Science (PLoS) |
Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
References | RS Zheng (pone.0262822.ref003) 2019; 41 RS Herbst (pone.0262822.ref004) 2018; 553 R Ramlau (pone.0262822.ref024) 2017; 14 H Sasaki (pone.0262822.ref023) 2006; 54 S Pilotto (pone.0262822.ref018) 2017; 5 X Xue (pone.0262822.ref026) 2020; 10 Q Deng (pone.0262822.ref014) 2018; 4 YL Zhang (pone.0262822.ref019) 2016; 7 TS Mok (pone.0262822.ref006) 2009; 361 S Vyse (pone.0262822.ref013) 2019; 4 B Pesch (pone.0262822.ref025) 2012; 131 AT Shaw (pone.0262822.ref007) 2013; 368 CM Blakely (pone.0262822.ref016) 2012; 2 F Bray (pone.0262822.ref002) 2018; 68 AT Shaw (pone.0262822.ref008) 2014; 371 O Gautschi (pone.0262822.ref011) 2017; 35 Y Zhang (pone.0262822.ref020) 2015; 94 SV Sharma (pone.0262822.ref005) 2007; 7 I Ferrer (pone.0262822.ref012) 2018; 124 D Planchard (pone.0262822.ref009) 2016; 17 RL Siegel (pone.0262822.ref001) 2016; 66 ME Arcila (pone.0262822.ref017) 2013; 12 C Stapelfeld (pone.0262822.ref027) 2020; 146 LV Sequist (pone.0262822.ref015) 2011; 3 CC Ho (pone.0262822.ref022) 2017; 12 AM Chapman (pone.0262822.ref021) 2016; 102 F Skoulidis (pone.0262822.ref010) 2021; 384 |
References_xml | – volume: 94 start-page: e1949 issue: 44 year: 2015 ident: pone.0262822.ref020 article-title: The Difference of Clinical Characteristics Between Patients With Exon 19 Deletion and Those With L858R Mutation in Nonsmall Cell Lung Cancer publication-title: Medicine doi: 10.1097/MD.0000000000001949 contributor: fullname: Y Zhang – volume: 7 start-page: 78985 issue: 48 year: 2016 ident: pone.0262822.ref019 article-title: The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis publication-title: Oncotarget doi: 10.18632/oncotarget.12587 contributor: fullname: YL Zhang – volume: 12 start-page: 567 issue: 3 year: 2017 ident: pone.0262822.ref022 article-title: Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib publication-title: Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer doi: 10.1016/j.jtho.2016.11.2231 contributor: fullname: CC Ho – volume: 102 start-page: 122 year: 2016 ident: pone.0262822.ref021 article-title: Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers publication-title: Lung Cancer doi: 10.1016/j.lungcan.2016.10.010 contributor: fullname: AM Chapman – volume: 10 start-page: 1251 year: 2020 ident: pone.0262822.ref026 article-title: Catalog of Lung Cancer Gene Mutations Among Chinese Patients publication-title: Frontiers in oncology doi: 10.3389/fonc.2020.01251 contributor: fullname: X Xue – volume: 68 start-page: 394 issue: 6 year: 2018 ident: pone.0262822.ref002 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA: a cancer journal for clinicians contributor: fullname: F Bray – volume: 14 start-page: 5611 issue: 5 year: 2017 ident: pone.0262822.ref024 article-title: Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland publication-title: Oncology letters contributor: fullname: R Ramlau – volume: 66 start-page: 7 issue: 1 year: 2016 ident: pone.0262822.ref001 article-title: Cancer statistics, 2016 publication-title: CA: a cancer journal for clinicians contributor: fullname: RL Siegel – volume: 2 start-page: 872 issue: 10 year: 2012 ident: pone.0262822.ref016 article-title: Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance publication-title: Cancer discovery doi: 10.1158/2159-8290.CD-12-0387 contributor: fullname: CM Blakely – volume: 361 start-page: 947 issue: 10 year: 2009 ident: pone.0262822.ref006 article-title: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma publication-title: The New England journal of medicine doi: 10.1056/NEJMoa0810699 contributor: fullname: TS Mok – volume: 3 start-page: 75ra26 issue: 75 year: 2011 ident: pone.0262822.ref015 article-title: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors publication-title: Science translational medicine doi: 10.1126/scitranslmed.3002003 contributor: fullname: LV Sequist – volume: 4 start-page: e01031 issue: 12 year: 2018 ident: pone.0262822.ref014 article-title: Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients publication-title: Heliyon doi: 10.1016/j.heliyon.2018.e01031 contributor: fullname: Q Deng – volume: 12 start-page: 220 issue: 2 year: 2013 ident: pone.0262822.ref017 article-title: EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics publication-title: Molecular cancer therapeutics doi: 10.1158/1535-7163.MCT-12-0620 contributor: fullname: ME Arcila – volume: 146 start-page: 2376 issue: 9 year: 2020 ident: pone.0262822.ref027 article-title: Sex-specificity in lung cancer risk publication-title: International journal of cancer doi: 10.1002/ijc.32716 contributor: fullname: C Stapelfeld – volume: 4 start-page: 5 year: 2019 ident: pone.0262822.ref013 article-title: Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer publication-title: Signal transduction and targeted therapy doi: 10.1038/s41392-019-0038-9 contributor: fullname: S Vyse – volume: 5 start-page: 2 issue: 1 year: 2017 ident: pone.0262822.ref018 article-title: MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy publication-title: Annals of translational medicine doi: 10.21037/atm.2016.12.33 contributor: fullname: S Pilotto – volume: 553 start-page: 446 issue: 7689 year: 2018 ident: pone.0262822.ref004 article-title: The biology and management of non-small cell lung cancer publication-title: Nature doi: 10.1038/nature25183 contributor: fullname: RS Herbst – volume: 131 start-page: 1210 issue: 5 year: 2012 ident: pone.0262822.ref025 article-title: Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case-control studies publication-title: International journal of cancer doi: 10.1002/ijc.27339 contributor: fullname: B Pesch – volume: 371 start-page: 1963 issue: 21 year: 2014 ident: pone.0262822.ref008 article-title: Crizotinib in ROS1-rearranged non-small-cell lung cancer publication-title: The New England journal of medicine doi: 10.1056/NEJMoa1406766 contributor: fullname: AT Shaw – volume: 35 start-page: 1403 issue: 13 year: 2017 ident: pone.0262822.ref011 article-title: Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry publication-title: Journal of clinical oncology: official journal of the American Society of Clinical Oncology doi: 10.1200/JCO.2016.70.9352 contributor: fullname: O Gautschi – volume: 368 start-page: 2385 issue: 25 year: 2013 ident: pone.0262822.ref007 article-title: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer publication-title: The New England journal of medicine doi: 10.1056/NEJMoa1214886 contributor: fullname: AT Shaw – volume: 384 start-page: 2371 issue: 25 year: 2021 ident: pone.0262822.ref010 article-title: Sotorasib for Lung Cancers with KRAS p.G12C Mutation publication-title: The New England journal of medicine doi: 10.1056/NEJMoa2103695 contributor: fullname: F Skoulidis – volume: 17 start-page: 642 issue: 5 year: 2016 ident: pone.0262822.ref009 article-title: Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial publication-title: The Lancet Oncology doi: 10.1016/S1470-2045(16)00077-2 contributor: fullname: D Planchard – volume: 41 start-page: 19 issue: 1 year: 2019 ident: pone.0262822.ref003 article-title: Report of cancer epidemiology in China, 2015 publication-title: Zhonghua zhong liu za zhi contributor: fullname: RS Zheng – volume: 7 start-page: 169 issue: 3 year: 2007 ident: pone.0262822.ref005 article-title: Epidermal growth factor receptor mutations in lung cancer publication-title: Nature reviews Cancer doi: 10.1038/nrc2088 contributor: fullname: SV Sharma – volume: 124 start-page: 53 year: 2018 ident: pone.0262822.ref012 article-title: KRAS-Mutant non-small cell lung cancer: From biology to therapy publication-title: Lung Cancer doi: 10.1016/j.lungcan.2018.07.013 contributor: fullname: I Ferrer – volume: 54 start-page: 103 issue: 1 year: 2006 ident: pone.0262822.ref023 article-title: L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer publication-title: Lung Cancer doi: 10.1016/j.lungcan.2006.06.003 contributor: fullname: H Sasaki |
SSID | ssj0053866 |
Score | 2.435447 |
Snippet | Non-small cell lung cancer (NSCLC) is the most common cancer type in China. Targeted therapies have been used to treat NSCLC for two decades, which is only... Background Non-small cell lung cancer (NSCLC) is the most common cancer type in China. Targeted therapies have been used to treat NSCLC for two decades, which... Background Non-small cell lung cancer (NSCLC) is the most common cancer type in China. Targeted therapies have been used to treat NSCLC for two decades, which... BACKGROUNDNon-small cell lung cancer (NSCLC) is the most common cancer type in China. Targeted therapies have been used to treat NSCLC for two decades, which... |
SourceID | plos doaj pubmedcentral proquest gale crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | e0262822 |
SubjectTerms | Adenocarcinoma Adenocarcinoma of Lung - epidemiology Adenocarcinoma of Lung - genetics Adenocarcinoma of Lung - pathology Adenocarcinoma of Lung - therapy Aged Alcohol Analysis Biology and Life Sciences Biopsy Bronchoscopy Cancer therapies Carcinoma, Non-Small-Cell Lung - epidemiology Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - therapy Care and treatment Chemotherapy Crizotinib Deletion Diagnosis Dosage and administration Epidermal growth factor Epidermal growth factor receptors Female Gender Genetic diversity Genetic variation Glomerular filtration rate Histology Hospitals Humans Lung cancer Lung cancer, Non-small cell Lung diseases Lung Neoplasms - epidemiology Lung Neoplasms - genetics Lung Neoplasms - pathology Lung Neoplasms - therapy Male Measurement Medicine and Health Sciences Metastasis Middle Aged Mortality Mutation Neoplasm Proteins - genetics Neoplasm Proteins - metabolism Non-small cell lung carcinoma Pathology Patients Prevalence Radiation therapy Retrospective Studies Risk factors Sex Factors Small cell lung carcinoma Smoking Squamous cell carcinoma Standardization Statistical analysis Statistical methods Subgroups Tumors |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQnrggyquBAgYhAYe0seNXjmVFVRAqEqWot8iOnXYllKz2UalXfjnjR6IGVYIDx41ns7vzje1vsjOfEXpTSaqcbXluWlPkTBU2r5xmOeVt6XTbcBerfE_E8Rn7fM7Pbxz15WvCojxwdNxBY6XhtBWq1SVTrdKOAsNWpYKdqXI2UiPCh2QqrsFgIERqlCslOUi47C_7zu1D1uFrJycbUdDrH1fl2fJnv76Ncv5ZOXljKzq6j-4lDokP43ffQXdc9wDtpFm6xu-SlPT7h-iXV2jSoa8I9y2OZd_O4th1dZ2HThZ4DVHkmxnxFWTO8REeXnT45HT-ZY51F-wXK7waCucuF0vsH-Di2FfZ-2ONh0UUN1MJ6Efo7Ojj9_lxnk5dyBvByCb3inZNxUvnmGgsKTlzVAtAjdrCakOMY7wStjWESUmY0aQwEmAxVJdGAsSP0awDP-8izCyk6kB4SNlQZgzTQHcsY7CkVkqWsslQPkBQL6O4Rh3-YZOQlERf1h6yOkGWoQ8ep9HWS2OHCxAwdQqY-m8Bk6GXHuU69pmOE7w-FFWQaS7gY14HCy-P0fn6mwu9Xa_rT19__IPR6beJ0dtk1PYQL41OPQ_wm7zs1sRyb2IJk7yZDO_6mBy8sq7BIZBpAxfj8M4hTm8ffjUO-5v6mrrO9dtgQykkWIJk6EkM69GzJQeeB9w5Q3IS8BPXT0e6xWVQJ1eec1bq6f_A6hm6S327SUFySvbQbLPauudAAjfmRZjvvwFYnl3_ priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Public Health Database dbid: 8C1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELbKcuGCKK8uFDAICTi4mziO7ZxQWVEVhIpEKeot8ivtSihZ9oHElV_OjPOAoApx3PXsbnYezowz3zeEPC8U18FXObOVTZjQiWdFMILxvMqCqVwe2i7fE3l8Jt6f5-c75LjHwmBbZb8nxo3aNw7PyGdcQmxBepLlM2PxFMBtZq-X3xjOj8LnrN0wjWvkegouikMc9Hxo9oColrIDzmUqnXV2Olg2dTiAKgR7KUc3psjfP-zSk-XXZn1VCvp3J-Uft6ajW-Rml1PSw9YJdslOqG-T3S5q1_RlRy396g75iYxNJuKMaFPRtg08eNqisH6wiGyB1-BVCG6k36GSbo_06KKmJ6fzD3Nq6ii_WNFV30h3uVhSPNClLc6ywTHH_aZK3ZgS-i45O3r7eX7MuikMzEmRbhgy3Lkiz0IQ0nnQvwjcSLAi94k3NrVB5IX0lU2FUqmwJk2s0gYqdpNZBSa_RyY16HmPUOGhdIcEKM0cF9YKA-mPFwK22EKrTLkpYb0JymVLtlHGJ24KipRWlyWarOxMNiVv0E6DLFJlxzea1UXZRV7pvLI5r6SuTCZ0BVfGoUTTmYbUpgjeTMkTtHLZ4k6HgC8PZRFpmxP4mWdRAukyauzHuTDb9bp89_HLfwidfhoJveiEqgZd2HQYCPhPSMM1ktwfSULQu9HyHvpkr5V1-Ts84JO9n169_HRYxi_FHrs6NNsowzkUXDKdkvutWw-azXLI-yCXnhI1cviR6scr9eIyspVrzEEL_eDfl_WQ3OAILElSxtN9MtmstuERpHsb-zhG8i-ZQFix priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELbKcuGCKK-mFDAICTh4FT8SJweEyoqqICgSZVFvlh077UpVsmx2Eb3yyxk7DxG0SD1mPXnszNj5Jp75BqEXuWSZs2VCTGliIrLYktxpQVhScqfLInFtlu9JejwXH8-Ssx3U92ztFNhsDe18P6n56nL668fVW5jwb0LXBkn7k6bLunJTiCl8ZuQNdJMJLrzPfxbDvgLM7rB76VELSVnMu2K6_11l9LIKnP7Dyj1ZXtbNNlj6b3blX6-rozvodocz8WHrGLtox1V30W43kxv8qqObfn0P_fYsTjrUHuG6xG1quLO4rcy6IqHaBY7B03zBI_4J0XX7mQ8vKnxyOvs0w7oK8osVXvXJdReLJfYfeXFbe1n71sf9QouLMU30fTQ_ev9tdky6zgykSAVdE896V-QJd06khaU8EY7pFCzLbGy1ocaJJE9taaiQkgqjaWxkpiGK19xIcIMHaFKBnvcQFhbCeQBFlBdMGCM0QCIrBCy7eSa5LCJEehOoZUvAocIunITApdWl8iZTncki9M7baZD19Nnhh3p1rrrZqAorTcLKNCs1F1kJT8YgbMt4BnAnd1ZH6Km3smprUYdFQB2meaByjuE2z4OEp9CofI7Oud40jfrw5fs1hE6_joRedkJlDf5S6K4uAv6Tp-YaSR6MJGEhKEbDe94ne600ChQC0TjgtQTO7P10-_CzYdhf1OfdVa7eBBnGIAhLaYQetm49aJYngAUBX0dIjhx-pPrxSLW4CAzmmcelebZ_Hf08QreYLzmJKWH0AE3Wq417DEBwbZ6Euf0HYGde8w priority: 102 providerName: Scholars Portal |
Title | Prevalence of targeted therapy-related genetic variations in NSCLC and their relationship with clinicopathological characteristics |
URI | https://www.ncbi.nlm.nih.gov/pubmed/35061839 https://www.proquest.com/docview/2621916135/abstract/ https://search.proquest.com/docview/2622288261 https://pubmed.ncbi.nlm.nih.gov/PMC8782298 https://doaj.org/article/cd7b52f68fa348f8ae27538388129eda http://dx.doi.org/10.1371/journal.pone.0262822 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLe2IqFd0MbXykYxCAk4pI0_EjvHrWoZiJVpY6i3yHacrdKWVP1A4sKBv5xnJ6kWtAPiYin1S5u8L7_nvvczQm8TQaXN8ijQuQ4DLsMsSKziAY1yZlVuIltV-U7ik0v-eRpNt1DU9ML4on2jZ_3i5rZfzK59beX81gyaOrHB2elQumUtkYNttC0Ya1L0yv2CAcdx3SPHBBnUIunPy8L2IeFwZZM76CGLYCGT7ojwO8uRR-3f-ObO_KZc3hd4_l0_eWdBGu-iR3UkiY-qJ95DW7Z4jPZqW13i9zWg9Icn6LfDaVK-uwiXOa6Kv22Gq96rn4HvZ4Fr0CXX0oh_QP5cbeThWYEnF8MvQ6wKTz9b4EVTPnc9m2O3jYur7srSHW7cuFJs2kDQT9HlePRteBLUZy8EJuZkFThcO5NEzFoem4ywiFuqYpAdzcJMaaItj5I4yzXhQhCuFQm1kArydMW0AEE_Q50CWL6PMM8gYYewhzBDudZcQdCTcQ6ONZGCCdNFQSOCdF5BbKT-fzYBqUnFy9RJL62l10XHTk4bWgeQ7T8oF1dprSapyYSOaB7LXDEuc3gyComZZBICmsRmqoteOSmnVbfpxszTozjxYM0h_MwbT-FAMgpXhXOl1stl-unr938gujhvEb2rifIS9MWouvMB3smBb7UoD1uUYOqmNb3vdLLhyjIFhkC-DRFZBHc2enr_9OvNtPtSV1lX2HLtaSiFNCsmXfS8UusNZxsj6SLRUvgW69szYLIeo7w20Rf_fecB2qGu0yQkASWHqLNarO1LiP9WugdWPxUwyiFx4_hjDz04Hk3Oznt-RwXGUy7d-GvU877hD_ezZYM |
link.rule.ids | 230,315,733,786,790,870,891,2115,2236,12083,12250,12792,21416,24346,27957,27958,31754,31755,33301,33302,33408,33409,33779,33780,43345,43614,43635,43840,53827,53829,74102,74371,74392,74659 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9NAEF5BOMAFUV4NFLogJODg1l6v1_YJlYgqhRAk2qLerH25jYTsECeVeuWXM7NeG4wqxDHeiePMY3dmPd-3hLzKU5ZZUyaBKlUY8Cw0QW4lD1hSxlaWOrFtl-9cTE_5x7PkzG-4Nb6tspsT3URtao175PtMQGxBehIn75Y_Ajw1Ct-u-iM0bpJbPIaFBpHik77FA2JZCA-Xi9No31tnb1lXdg9qD-ygHCxHjrW_n5tHy-91c13i-Xf_5B8L0uE9ctdnkvSgNf0WuWGr-2TLx2pD33hC6bcPyE_kaZIOXUTrkrbN39bQFnt1FTg8C3wGX0JII72E-rndyKOLis6PJ7MJlZWTX6zoqmufu1gsKW7j0hZdWePhxt1USvWQCPohOT38cDKZBv7shUALHq0D5LXTeRJby4U2oHVumRRgO2ZCI1WkLE9yYUoV8TSNuJJRqNJMQp0uY5WCoR-RUQV63iaUGyjYIe2JYs24UlxC0mM4h4k1z9I41WMSdCYoli3FRuHes6VQmrS6LNBkhTfZmLxHO_WySJDtLtSr88LHW6FNqhJWiqyUMc9KeDIGhVkWZ5DQ5NbIMdlFKxct2rQP8-JA5I6sOYSfeekkkCSjwi6cc7lpmuLoy7f_EDr-OhB67YXKGvxFS498gP-E5FsDyZ2BJIS6Hgxvo092WmmK30EB3-z89PrhF_0w3hQ76ypbb5wMY1BmiWhMHrdu3Ws2TiDbgwx6TNKBww9UPxypFheOozzDzDPPnvz7sXbJ7enJ51kxO5p_ekruMISWhFHAoh0yWq829hkkfGv13EX1Lwc8V-c |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELegSIgXxPhaYDCDkICHrInjOMkTGoWywVQQY9PeIju2t0ooKU2LxCt_OXeOUwiaEI-tr216X_mdc_czIc-KjOVG2zRUVkUhzyMdFkbykKU2MdJWqem6fGfi4IS_P0vPfP9T69sq-5zoErVuKtwjHzMBsQXwJEnH1rdFfHozfbX4FuIJUvik1R-ncZVcQ5CNpxnk03d9Voa4FsKPziVZPPaW2ls0tdmDOgS7KQe3Jsfgv8nTo8XXpr0MhP7dS_nHzWl6i9z0qJLud26wRa6Y-jbZ8nHb0heeXPrlHfITOZukmzSijaVdI7jRtJvD-hG62RZ4DX6F4430O9TS3aYendd0djw5mlBZO_n5ki77VrqL-YLili7tJi0bPOi4T6u0GpJC3yUn07dfJgehP4chrASPVyFy3FVFmhjDRaXBAtwwKcCOTEdaqlgZnhZCWxXzLIu5knGkslxCzS4TlYHR75FRDXreJpRrKN4BAsVJxbhSXAIA0pxDki3yLMmqgIS9CcpFR7dRumduGZQpnS5LNFnpTRaQ12injSySZbs3muV56WOvrHSmUmZFbmXCcwtXxqBIy5McwE1htAzILlq57CZPNyFf7ovCETdH8DNPnQQSZtToeudy3bbl4cfT_xA6_jwQeu6FbAP-Ukk_BQH_CYm4BpI7A0kI-2qwvI0-2WulLX8HCHyy99PLl59slvFLscuuNs3ayTAGJZeIA3K_c-uNZpMUkB-g6YBkA4cfqH64Us8vHF95jii0yB_8-7J2yXUI6PLocPbhIbnBcMokikMW75DRark2jwD7rdRjF9S_AJvxXFE |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prevalence+of+targeted+therapy-related+genetic+variations+in+NSCLC+and+their+relationship+with+clinicopathological+characteristics&rft.jtitle=PloS+one&rft.au=Li%2C+Fanghua&rft.au=Ye%2C+Peng&rft.au=Cai%2C+Peiling&rft.au=Dong%2C+Dandan&rft.date=2022-01-21&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=17&rft.issue=1&rft.spage=e0262822&rft_id=info:doi/10.1371%2Fjournal.pone.0262822&rft.externalDBID=ISR&rft.externalDocID=A690095902 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |